BEAM
Price
$35.41
Change
+$0.86 (+2.49%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
3.51B
48 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$5.81
Change
+$0.65 (+12.60%)
Updated
Jan 14 closing price
Capitalization
452.66M
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs SLDB

Header iconBEAM vs SLDB Comparison
Open Charts BEAM vs SLDBBanner chart's image
Beam Therapeutics
Price$35.41
Change+$0.86 (+2.49%)
Volume$34.45K
Capitalization3.51B
Solid Biosciences
Price$5.81
Change+$0.65 (+12.60%)
Volume$1.97M
Capitalization452.66M
BEAM vs SLDB Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. SLDB commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and SLDB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (BEAM: $34.55 vs. SLDB: $5.16)
Brand notoriety: BEAM and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 125% vs. SLDB: 113%
Market capitalization -- BEAM: $3.51B vs. SLDB: $402.02M
BEAM [@Biotechnology] is valued at $3.51B. SLDB’s [@Biotechnology] market capitalization is $402.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 4 bearish.
  • SLDB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than SLDB.

Price Growth

BEAM (@Biotechnology) experienced а +21.91% price change this week, while SLDB (@Biotechnology) price change was -6.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.51B) has a higher market cap than SLDB($453M). BEAM YTD gains are higher at: 24.639 vs. SLDB (-8.511). SLDB has higher annual earnings (EBITDA): -170.67M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. SLDB (236M). SLDB has less debt than BEAM: SLDB (21.9M) vs BEAM (151M). BEAM has higher revenues than SLDB: BEAM (55.7M) vs SLDB (0).
BEAMSLDBBEAM / SLDB
Capitalization3.51B453M774%
EBITDA-434.55M-170.67M255%
Gain YTD24.639-8.511-290%
P/E RatioN/AN/A-
Revenue55.7M0-
Total Cash1.08B236M456%
Total Debt151M21.9M689%
FUNDAMENTALS RATINGS
BEAM vs SLDB: Fundamental Ratings
BEAM
SLDB
OUTLOOK RATING
1..100
7855
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3861
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (21) in the Biotechnology industry is in the same range as BEAM (37) in the null industry. This means that SLDB’s stock grew similarly to BEAM’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that SLDB’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's SMR Rating (97) in the null industry is in the same range as SLDB (98) in the Biotechnology industry. This means that BEAM’s stock grew similarly to SLDB’s over the last 12 months.

BEAM's Price Growth Rating (38) in the null industry is in the same range as SLDB (61) in the Biotechnology industry. This means that BEAM’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that SLDB’s stock grew significantly faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMSLDB
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMFGX506.862.41
+0.48%
Vanguard S&P Mid-Cap 400 Growth Idx I
SSQSX15.45-0.03
-0.19%
State Street Instl Small-Cap Equity Svc
WQAIX14.17-0.05
-0.35%
Westwood Quality AllCap Institutional
VSIEX22.55-0.14
-0.62%
JPMorgan International Equity I
MGFZX8.31-0.06
-0.72%
MassMutual Global I

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+2.55%
CRSP - BEAM
71%
Closely correlated
+1.59%
RXRX - BEAM
62%
Loosely correlated
-2.49%
NTLA - BEAM
61%
Loosely correlated
+2.71%
PRME - BEAM
59%
Loosely correlated
-2.80%
SYRE - BEAM
57%
Loosely correlated
-3.87%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-1.53%
EDIT - SLDB
50%
Loosely correlated
-1.88%
DSGN - SLDB
49%
Loosely correlated
+4.93%
RGNX - SLDB
46%
Loosely correlated
-0.20%
SYRE - SLDB
45%
Loosely correlated
-3.87%
BEAM - SLDB
45%
Loosely correlated
+2.55%
More